Showing results (1-10 of 15) with videos related to

Sort By:
Pageof 2
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 20, 2020
Emerging Treatment Paradigms for EGFR-Mutant Lung Cancers Progressing on Osimertinib: A ReviewAndrew J Piper-Vallillo, Lecia V Sequist, Zofia Piotrowska
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 27, 2024
Management of Treatment Resistance in Patients With Advanced Epidermal Growth Factor Receptor-Mutated Lung Cancer: Personalization, Parsimony, and PartnershipAndrew J Piper Vallillo, Hollis Viray, Jill Feldman, et al.
The Journal of Biological Chemistry|March 22, 2017
Differential involvement of the microtubule cytoskeleton in insulin receptor substrate 1 (IRS-1) and IRS-2 signaling to AKT determines the response to microtubule disruption in breast carcinoma cellsJose Mercado-Matos, Jennifer L Clark, Andrew J Piper, et al.
Precision Cancer Medicine|August 11, 2020
Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?Kartik Sehgal, Andrew J Piper-Vallillo, Hollis Viray, et al.
Medrxiv : the Preprint Server for Health Sciences|August 4, 2020
Time to SARS-CoV-2 Clearance Among Patients with Cancer and COVID-19Wenxin Xu, Andrew J Piper-Vallillo, Poorva Bindal, et al.
Cancer Medicine|February 9, 2021
Time to SARS-CoV-2 clearance among patients with cancer and COVID-19Wenxin Xu, Andrew J Piper-Vallillo, Poorva Bindal, et al.
Plos One|August 9, 2019
Insulin Receptor Substrate-1 (IRS-1) and IRS-2 expression levels are associated with prognosis in non-small cell lung cancer (NSCLC)Andrew J Piper, Jennifer L Clark, Jose Mercado-Matos, et al.
Cancers|March 28, 2024
A Real-World Study of Patient Characteristics and Clinical Outcomes in EGFR Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical PracticeHollis Viray, Andrew J Piper-Vallillo, Page Widick, et al.
Physical Review Letters|March 7, 2025
Attosecond Clocking and Control of Strong Field Quantum TrajectoriesAndrew J Piper, Qiaoyi Liu, Abraham Camacho Garibay, et al.
Lung Cancer (Amsterdam, Netherlands)|September 8, 2022
Complete pathologic response to short-course neoadjuvant alectinib in mediastinal node positive (N2) ALK rearranged lung cancerDaniel Sentana-Lledo, Hollis Viray, Andrew J Piper-Vallillo, et al.
Pageof 2